Evidence map›Paper›PMID 40111937›Full record

ArticleJournal of Alzheimer's disease : JAD2025

Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting.

Anders Wimo, Ron Handels, Kaj Blennow, Bjørn-Eivind Kirsebom, Per Selnes, Jaka Bon, Andreja Emersic, Fernando Gonzalez-Ortiz, Milica Gregoric Kramberger, Anders Sköldunger and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anders WimoDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden.ORCID 0000-0003-0963-5750
Ron HandelsDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden.ORCID 0000-0002-8663-0630
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-1890-4193
Bjørn-Eivind KirsebomDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway.ORCID 0000-0002-1413-9578
Per SelnesInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-5131-9757
Jaka BonDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0009-0008-0256-8640
Andreja EmersicDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0009-0006-8229-2706
Fernando Gonzalez-OrtizDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-7897-9456
Milica Gregoric KrambergerDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0001-8231-1176
Anders SköldungerDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden.ORCID 0000-0001-8439-2248
Andreja SpehDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0002-1300-6730
Santiago Timón-ReinaDepartment of Neurology, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0003-3652-1820
Ellen VromenAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands.ORCID 0000-0001-7774-5500
Pieter Jelle VisserAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands.ORCID 0000-0001-8008-9727
Bengt WinbladDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, BioClinicum J9:20, Karolinska Institutet, Solna, Sweden.ORCID 0000-0002-0011-1179
Tormod FladbyDepartment of Neurology, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0002-9984-9797

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundThe introduction of anti-amyloid treatments (AAT) for Alzheimer's disease (AD) has put the cost-effectiveness into focus.ObjectiveEstimate the potential cost-effectiveness of diagnostic pathways combined with AAT for early AD.MethodsDiagnostic accuracy of blood-based (BBM) and cerebrospinal fluid (CSF) biomarkers was obtained from Norwegian memory clinics using positron emission tomography (PET) as reference standard. In a health-economic model, the cost-effectiveness of three diagnostic strategies was estimated relying either on BBM (p-tau 217), CSF (Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesCost-Benefit AnalysisAgedBiomarkersCognitive DysfunctionFemaleHumansMaleNorwayPeptide FragmentsPositron-Emission TomographyQuality-Adjusted Life Yearstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseaseanti-amyloid treatmentbiomarkersblood-based biomarkerscost-effectivenessdisease modifying treatmentdonanemablecanemab

Identifiers

PMID40111937
PMCPMC12231775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.